Answering commonly asked Zenrelia questions

Now that Elanco's Zenrelia has received FDA approval and hit the veterinary market, there are veterinary professionals out there that are interested in learning more about the product, especially gaining a better understanding of the label added to the Zenrelia box.

During this exclusive interview with dvm360, Mara Tugel, DVM, veterinary technical marketing-companion animal therapeutics for Elanco, provides some clarity into the most common questions that are out there about Zenrelia.

Below is a partial transcript

Mara Tugel, DVM: The second question that we get most commonly is around why there's a boxed warning on this product, and what does this mean? So there is a boxed warning on the Zenrelia label that is around concurrent use with vaccines, and there's a holding period described in this boxed warning where you're supposed to discontinue use of Zenrelia for at least 28 days to 3 months prior to vaccination and at least 28 days after this, of course, is of major concern to general practitioners. The dermatologists say, I don't even know when dogs are getting vaccinated, but for general practitioners, this is something that we understand they need more information about.

The box warning is specifically related to the results of a vaccine response study in which dogs that were under 12 months of age were treated with 3 times the label dose of Zenrelia. We know that all of these immune modulatory drugs, including Jak inhibitors, can be immunosuppressive when they're dosed at higher than labeled doses.

Learn more about Zenrelia here.

Interested in learning more about treating pruritis? Fetch Coastal will feature sessions presented by Joya Griffin, DVM, DACVD, and Natalie Marks, DVM, CVJ, CCFP, Elite FFCP-V,s. Learn more and register here today.